Mediterranean diet for psoriasis patients on biologic therapy
Part of Skin clinical trials.
This study tests whether adding a Mediterranean diet to your psoriasis treatment can improve your skin. You will be asked to follow a heart-healthy diet for several months while taking a new biologic medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had plaque psoriasis for at least 1 year.
- Your psoriasis is moderate to severe, covering at least 5% of your body or with thick, red, scaly patches.
- You are about to start a biologic medicine (like secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, or tildrakizumab) for your psoriasis.
- You are generally healthy (except for psoriasis) and have a BMI between 25 and 40, so you are eligible for a weight loss program.
- You do not have a nut allergy or any other serious health conditions (like active infections, certain cancers, or inflammatory bowel disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a full-body PET scan to see if switching to a balanced, nutritious diet can lower inflammation throughout the body and in the skin for people with psoriasis. It may help if you are overweight and have a poor diet.
This trial tests if adding a gluten-free, low-histamine anti-inflammatory diet, and in some cases physical therapy, helps children with mild-to-moderate plaque psoriasis. It aims to see if these lifestyle changes can improve skin symptoms when combined with usual treatment.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This study looks at how blood sugar control (including diabetes) changes immune cells in the skin for people with moderate to severe plaque psoriasis. It may help researchers understand what drives psoriasis and how it could respond to future treatments.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.